21 completed, 11 recruiting, 5 terminated, 4 active not recruiting. 21 Phase 2, 14 Phase 1, 7 Not applicable, 4 Phase 3, 2 Early Phase 1.
Follow Myelodysplastic Syndromes (MDS): new trials by email Literature Review of Myelodysplastic Syndromes (MDS) trials Research Report on Myelodysplastic Syndromes (MDS)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes Dapagliflozin (10mg Tab) - Myelodysplastic Syndromes (MDS), Anemia | Phase 2 | Not yet recruiting | Seug yun Yoon, MD | 37 | 2026-09-01 | 2026-04-08 |
| Asia Myelodysplastic Syndrome (MDS) Registry Prescribed treatments for myelodysplastic syndromes (MDS) - Myelodysplastic Syndromes (MDS) | Recruiting | Bristol-Myers Squibb | 500 | 2026-08-11 | 2026-10-08 | |
| Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML Mitoxantrone Hydrochloride Liposome, Cytarabine, Granulocyte Colony-Stimulating Factor(G-CSF) - Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) | Phase 3 | Not yet recruiting | Ruijin Hospital | 168 | 2026-07-30 | 2026-07-29 |
| Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT Prophylactic DLI, Preemptive DLI - Acute Myeloid Leukemia, Myelodysplastic Syndromes (MDS) | Not applicable | Not yet recruiting | Peking University People's Hospital | 200 | 2026-01-01 | 2026-01-06 |
| Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor Ruxolitinib, Abatacept (Orencia) - Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia | Phase 2 | Recruiting | St. Petersburg State Pavlov Medical University | 60 | 2025-05-10 | 2025-11-20 |
| ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies ICP-248, Azacitidine - Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS) | Phase 1 | Recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | 266 | 2024-12-18 | 2026-08-18 |
| Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation Ivosidenib, Azacitidine - Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS) | Phase 3 | Recruiting | Institut de Recherches Internationales Servier | 48 | 2024-12-03 | 2026-09-03 |
| A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes Luspatercept, Epoetin Alfa - Myelodysplastic Syndromes (MDS) | Withdrawn | Bristol-Myers Squibb | 2024-11-30 | 2024-10-09 | ||
| A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept Luspatercept, Erythropoiesis-stimulating agent (ESA) - Myelodysplastic Syndromes (MDS) | Completed | Bristol-Myers Squibb | 430 | 2024-11-22 | 2026-09-30 | |
| CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial Autologous CAR123 T lymphocytes - Leukemia, Myeloid, Acute(AML), Precursor Cell Lymphoblastic Leukemia-Lymphoma | Early Phase 1 | Active not recruiting | Institute of Hematology and Blood Transfusion, Czech Republic | 18 | 2024-10-23 | 2026-09-14 |
| Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score - Hematologic Malignancy, Bone Marrow Transplant Rejection | Early Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 8 | 2024-09-19 | 2026-10-05 |
| Evaluation of Response to Biosimilar Erythropoietin Alfa Therapy in Anemic Patients With Myelodysplastic Syndrome Myelodysplastic Syndromes (MDS) | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 60 | 2024-08-30 | 2025-01-08 | |
| Cord Blood Transplant in Adults With Blood Cancers Conditioning Chemotherapy, Cord blood graft - Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 17 | 2023-05-22 | 2026-10-23 |
| Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances Cyclophosphamide, CAR.70/IL15-transduced CB-NK cells, Fludarabine phosphate - B-Cell Lymphoma, Myelodysplastic Syndromes (MDS) | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 80 | 2022-11-01 | 2026-08-07 |
| Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes Sodium Valproate, Bezafibrate, Medroxyprogesterone, Danazol - Myelodysplastic Syndromes (MDS) | Phase 2 | Unknown | Prof. Janet Dunn | 120 | 2021-12-21 | 2023-10-03 |
| Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant CHAMPS-II adapted to adults 60+ years in HCT setting - Leukemia, Lymphoma | Not applicable | Recruiting | University of Nebraska | 114 | 2021-11-18 | 2026-08-19 |
| A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes Pevonedistat, Decitabine, Cedazuridine - Myelodysplastic Syndromes (MDS) | Phase 2 | Withdrawn | Takeda | 2021-10-01 | 2021-09-29 | |
| Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies genetic study, Pharmacokinetic study, Study of phenotypic activity of cytidine deaminase - Myelodysplastic Syndromes (MDS), Leukemia Acute Myeloid - AML | Not applicable | Recruiting | Assistance Publique Hopitaux De Marseille | 70 | 2021-06-14 | 2026-10-28 |
| A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant Personalized rATG (P-rATG), Hyper fractionated total body irradiation, Thiotepa - Acute Myeloid Leukemia (AML), Acute Lymphoid Leukemia (ALL) | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 59 | 2021-04-30 | 2026-05-06 |
| Pharmacokinetics, Tolerability and Safety of NEX-18a NEX-18a injection, Azacitidine Injection - Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) | Phase 1 | Completed | Nanexa AB | 2 | 2021-04-27 | 2023-10-17 |
Showing 20 of 51. Sign in to see all of them.
Myelodysplastic Syndromes (51) · Leukemia, Myeloid, Acute (24) · Myeloproliferative Disorders (8) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (7) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Leukemia, Myelomonocytic, Chronic (6) · Anemia (5) · Leukemia (5) · Lymphoma, Non-Hodgkin (5) · Hodgkin Disease (4) · Multiple Myeloma (4) · Hematologic Neoplasms (3) · Lymphoma (3) · Leukemia, Myelomonocytic, Juvenile (2) · Recurrence (2)
Bone Marrow Diseases (51) · Hematologic Diseases (51) · Hemic and Lymphatic Diseases (51) · Neoplasms (30) · Neoplasms by Histologic Type (30) · Leukemia, Myeloid (27) · Leukemia (25) · Pathological Conditions, Signs and Symptoms (16) · Disease Attributes (15) · Pathologic Processes (15) · Chronic Disease (13) · Immune System Diseases (11) · Immunoproliferative Disorders (10) · Lymphatic Diseases (10) · Lymphoproliferative Disorders (10)
Azacitidine (11) · Cyclophosphamide (3) · Decitabine (3) · Panobinostat (3) · fludarabine (3) · luspatercept (3) · venetoclax (3) · Cytarabine (2) · Lenalidomide (2) · Melphalan (2) · Thiotepa (2) · fludarabine phosphate (2) · thymoglobulin (2) · ACE-011 (1) · ALT-803 (1)
Stanford University (4) · Bristol-Myers Squibb (3) · Memorial Sloan Kettering Cancer Center (3) · AbbVie (2) · Celgene (2) · Ascentage Pharma Group Inc. (1) · Assistance Publique Hopitaux De Marseille (1) · Beijing InnoCare Pharma Tech Co., Ltd. (1) · Cell Medica Ltd (1) · Dana-Farber Cancer Institute (1) · Daniel Bernstein (1) · Everett Meyer (1) · Goethe University (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Institut de Recherches Internationales Servier (1)
United States (29) · Germany (9) · United Kingdom (7) · Australia (6) · France (6) · Italy (6) · China (4) · Netherlands (4) · Canada (3) · Czechia (3) · Israel (3) · Japan (3) · Spain (3) · Sweden (3) · Taiwan (3)
Ajay Vora, MD, Prof. (1) · Amy DeZern, MD, MHS (1) · Ann Jakubowski, MD (1) · Barry Skikne, M.D., FACP; FCP (SA) (1) · Brandon Triplett, MD (1) · Bruno Carneiro de Medeiros (1) · Christian B Gocke, MD, PhD (1) · Daniel Bernstein (1) · David Bowen, PhD (1) · David Marin, MD (1) · Detlef Haase, MD, Prof. (1) · Emma Morris, MD (1)
PMID 18215785, PMID 23623559, PMID 25344522, PMID 26296092, PMID 26355708, PMID 27926979, PMID 28905323, PMID 29122992, PMID 29331635, PMID 29463563, PMID 30126931, PMID 30951840, PMID 31092732, PMID 31171638, PMID 31707794, PMID 32203268, PMID 32499241, PMID 33191169, PMID 34932836, PMID 36309981, PMID 36607832, PMID 36947201, PMID 37146263, PMID 38091578, PMID 39652823, PMID 39792934, PMID 39844769, PMID 39850648, PMID 39909656, PMID 41114449, PMID 41143386, PMID 41144785, PMID 41338864, PMID 41671442, PMID 41857682, PMID 41906220, PMID 42529759
2016 (2), 2023 (2), R01HL114591 (1), U24HL138660 (1)